Zelira says its 23-patient, phase Ib/IIa trial of marijuana-derived ZLT-101 has shown safety and statistical significance for reduction of chronic insomnia.

Zelira said that the randomised, double-blind, cross-over trial treated patients for 14 nights with ZTL-101 and 14 nights of placebo, separated by a one-week washout period at the University of Western Australia Centre for Sleep Science.

Biotech Daily – Zelira: Marijuana ZLT-101 ‘Effective For Insomnia’